Cirrus Pharmaceuticals, Inc. has expanded its current capacity for stability storage with the addition of 3 LUWA walk-in stability chambers. The company will add three large capacity, cGMP compliant chambers, each with 1,100 cubic feet of storage space. The new additions include: 25°C / 60% RH storage (long-term conditions); 30°C / 65% RH storage (Intermediate conditions); and 40°C / 75% RH storage (Accelerated Conditions)
   
“With an increase in our existing and new client sponsor requests for long-term stability storage and testing, expanding our capacity is a logical investment in Cirrus Pharmaceuticals’ progression as a contract research service provider,” said Jean-Marc Bovet, Ph.D. executive senior vice president.
   
With the expansion, Cirrus will be able to increase its current capabilities of formulation and product development services for various dosage forms including inhalation, nasal, parenteral, oral, topical and transdermal. The expansion also enhances its release testing and stability testing in support of clinical trials, IND and NDA submissions. Validation of the chambers, including temperature and humidity mapping and monitoring systems, are scheduled for completion by November of this year.